Salaffi Fausto, Farah Sonia, Di Donato Eleonora, Sonnati Massimo, Filippucci Emilio, De Angelis Rossella, Gabbrielli Francesco, Di Carlo Marco
Rheumatology Unit, Università Politecnica delle Marche, "Carlo Urbani" Hospital, Via Aldo Moro, 25, 60035 Jesi, Italy.
Hippocrates Sintech Srl, 60035 Genova, Italy.
J Pers Med. 2025 Jan 16;15(1):30. doi: 10.3390/jpm15010030.
. Telecontrol approaches for rheumatoid arthritis (RA) management aim to enhance patient outcomes. This pilot study assessed whether the Rheumatoid Arthritis Impact of Disease (RAID) approach could be used during teleconsultations to monitor RA disease activity through a web-based platform called iARPlus (Innovative Approach in Rheumatology). . Forty RA patients participated in two in-person visits (baseline and 12 months) and seven teleconsultations over 12 months, collected via the iARPlus portal and accessible through an internet browser. Disease activity, at baseline and follow-up, was measured using the Clinical Disease Activity Index (CDAI) and self-reported RAID scores throughout the study. The RAID approach, developed by the European Alliance of Associations for Rheumatology (EULAR), combines key patient-reported outcomes (PROs). . Nineteen patients (mean age: 49.3 years) were treated with Janus kinase inhibitors (JAKis), and 21 patients (mean age: 48.1 years) received adalimumab. All patients had active disease (mean CDAI 27.9 ± 4.8). Strong correlations were found between CDAI and RAID scores at baseline (ρ = 0.809, < 0.0001) and at follow-up (ρ = 0.789, < 0.0001). JAKi-treated patients showed greater reductions in RAID scores, pain relief, and higher rates of disease remission compared to adalimumab-treated patients. . RAID scores were effective in teleconsultations for assessing RA disease activity. JAKi treatment resulted in better pain control and disease activity improvement compared to adalimumab. Further studies are needed to confirm the clinical and economic benefits of telecontrol for RA management.
类风湿关节炎（RA）管理的远程控制方法旨在改善患者预后。这项试点研究评估了类风湿关节炎疾病影响（RAID）方法是否可在远程会诊期间用于通过一个名为iARPlus（风湿病创新方法）的基于网络的平台监测RA疾病活动。40名RA患者参加了两次面对面就诊（基线和12个月时）以及12个月内的7次远程会诊，数据通过iARPlus门户收集并可通过互联网浏览器访问。在整个研究过程中，使用临床疾病活动指数（CDAI）和自我报告的RAID评分来测量基线和随访时的疾病活动。由欧洲风湿病协会联盟（EULAR）开发的RAID方法结合了关键的患者报告结局（PROs）。19名患者（平均年龄：49.3岁）接受了 Janus激酶抑制剂（JAKis）治疗，21名患者（平均年龄：48.1岁）接受了阿达木单抗治疗。所有患者均患有活动性疾病（平均CDAI 27.9±4.8）。在基线时（ρ = 0.809，<0.0001）和随访时（ρ = 0.789，<0.0001），CDAI与RAID评分之间发现了强相关性。与接受阿达木单抗治疗的患者相比，接受JAKi治疗的患者RAID评分降低幅度更大，疼痛缓解更明显，疾病缓解率更高。RAID评分在远程会诊中对于评估RA疾病活动是有效的。与阿达木单抗相比，JAKi治疗能更好地控制疼痛和改善疾病活动。需要进一步研究以证实RA管理中远程控制的临床和经济效益。
